COMMUNIQUÉS West-GlobeNewswire

-
MediPharm Labs Expands Leading CBN Oil Portfolio with The Launch of New Nighttime Inhaler
24/07/2025 -
Cannara obtient 5 inscriptions clés dans la nouvelle catégorie de cartouches de vapotage de la SQDC, y compris des cartouches de vapotage à base de rosine vivante à venir
24/07/2025 -
Cannara Secures 5 Key Listings in Québec’s New Vape Cartridge Category Including to be Released Live Rosin Vapes
24/07/2025 -
Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy
24/07/2025 -
The Joint Corp. to Host Conference Call on Thursday, August 7th to Discuss Second Quarter 2025 Results
24/07/2025 -
Alterity Therapeutics Announces Publication on Novel MRI Endpoint from the bioMUSE Natural History Study
24/07/2025 -
Regeneron Announces the 2025 Winners of the Regeneron Prize for Creative Innovation
24/07/2025 -
Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus Erythematosus
24/07/2025 -
Matchpoint Therapeutics Announces Exclusive Option and License Agreement with Novartis to Develop Oral Inhibitors for Multiple Inflammatory Diseases
24/07/2025 -
Collegium to Report Second Quarter 2025 Financial Results on August 7, 2025
24/07/2025 -
Jeune Announces Positive Results and Significant Aesthetic Improvements from Phase 1 Study of KB304 for Moderate to Severe Wrinkles of the Décolleté
24/07/2025 -
4DMT Announces Presentations at 43rd Annual Scientific Meeting of the American Society of Retina Specialists
24/07/2025 -
BioVie Presented Data Highlighting that Patients Treated with Bezisterim Potentially Experienced an Age Deceleration Advantage Compared to Placebo on 10 Different Biological Clocks at the 2nd World Conference on Aging and Gerontology
24/07/2025 -
Citryll Announces Formation of Scientific Advisory Board
24/07/2025 -
First half of 2025: Solid growth, investments and pipeline progress pave the way for two key launches in H2
24/07/2025 -
Communiqué de presse : Efluelda®, le vaccin haute dose de Sanofi contre la grippe, fait son retour en France pour la saison 2025-2026
24/07/2025 -
Aicuris Enrolled Last Participant in Pivotal Trial with Pritelivir to Treat Refractory Herpes Simplex Infection in Immunocompromised Patients
24/07/2025 -
argenx to Report Half Year 2025 Financial Results and Second Quarter Business Update on July 31, 2025
24/07/2025 -
[Ad hoc announcement pursuant to Art. 53 LR] Roche continues strong momentum with 7% growth (CER) in the first half of 2025
24/07/2025
Pages